PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM

Rang in aandelen #39392
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aandeelprijs
$0.11725176
Laatst gesynchroniseerd: 2025-07-14
Marktkapitalisatie
$481.50K
Verandering (1 dag)
-0.20%
Verandering (1 jaar)
-1.64%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Categorie

Healthcare
Aandelsplitsingen voor PHAXIAM Therapeutics S.A. (PHXM)
Het aandeel PHAXIAM Therapeutics S.A. (symbool: PHXM) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Oct 21, 2026.
Eén aandeel PHXM dat vóór Oct 21, 2026 werd gekocht, staat nu gelijk aan 0 aandelen PHXM.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL